Option Care Health, Inc. announced its financial results for the third quarter ended September 30, 2024. The company reported adjusted earnings per share of $0.41, surpassing the consensus estimate of $0.31 per share. This performance reflects the team's focus on delivering patient care despite various challenges.
The company also provided updated full-year 2024 revenue guidance, projecting between $4.9 billion and $4.95 billion, which is above the consensus estimate of $4.83 billion. This updated outlook indicates continued revenue momentum for the year.
However, Option Care Health disclosed a supply chain disruption impacting intravenous solution bags due to Hurricane Helene, which is expected to negatively affect fourth-quarter 2024 financial results, primarily within acute therapies. Furthermore, the company anticipates a 'drastic' and 'rapid' negative impact in early 2025 from biosimilar introductions, specifically related to STELARA pricing adjustments, which represents a significant future financial headwind.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.